240 related articles for article (PubMed ID: 31868071)
1. High-Throughput Screening Assays for Cancer Immunotherapy Targets: Ectonucleotidases CD39 and CD73.
Kumar M; Lowery R; Kumar V
SLAS Discov; 2020 Mar; 25(3):320-326. PubMed ID: 31868071
[TBL] [Abstract][Full Text] [Related]
2. [A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response].
Gros L; Paturel C; Perrot I; Bensussan A; Eliaou JF; Bastid J; Bonnefoy N
Med Sci (Paris); 2020 Feb; 36(2):112-115. PubMed ID: 32129745
[No Abstract] [Full Text] [Related]
3. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.
Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF
Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716
[TBL] [Abstract][Full Text] [Related]
4. Targeting the adenosine pathway for cancer immunotherapy.
Hammami A; Allard D; Allard B; Stagg J
Semin Immunol; 2019 Apr; 42():101304. PubMed ID: 31604539
[TBL] [Abstract][Full Text] [Related]
5. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
[TBL] [Abstract][Full Text] [Related]
6. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
Allard B; Longhi MS; Robson SC; Stagg J
Immunol Rev; 2017 Mar; 276(1):121-144. PubMed ID: 28258700
[TBL] [Abstract][Full Text] [Related]
7. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical and functional analysis of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and ecto-5'-nucleotidase (CD73) in pig aortic valves.
Kaniewska E; Sielicka A; Sarathchandra P; Pelikant-Małecka I; Olkowicz M; Słomińska EM; Chester AH; Yacoub MH; Smoleński RT
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):305-12. PubMed ID: 24940684
[TBL] [Abstract][Full Text] [Related]
9. The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine.
Passarelli A; Tucci M; Mannavola F; Felici C; Silvestris F
Tumour Biol; 2019 Apr; 42(4):1010428319837138. PubMed ID: 30957676
[TBL] [Abstract][Full Text] [Related]
10. Targeting adenosine and regulatory T cells in cancer immunotherapy.
Churov A; Zhulai G
Hum Immunol; 2021 Apr; 82(4):270-278. PubMed ID: 33610376
[TBL] [Abstract][Full Text] [Related]
11. CD39 and CD73 in immunity and inflammation.
Antonioli L; Pacher P; Vizi ES; Haskó G
Trends Mol Med; 2013 Jun; 19(6):355-67. PubMed ID: 23601906
[TBL] [Abstract][Full Text] [Related]
12. The Inhibition of CD39 and CD73 Cell Surface Ectonucleotidases by Small Molecular Inhibitors Enhances the Mobilization of Bone Marrow Residing Stem Cells by Decreasing the Extracellular Level of Adenosine.
Adamiak M; Bujko K; Brzezniakiewicz-Janus K; Kucia M; Ratajczak J; Ratajczak MZ
Stem Cell Rev Rep; 2019 Dec; 15(6):892-899. PubMed ID: 31520298
[TBL] [Abstract][Full Text] [Related]
13. Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints.
Baghbani E; Noorolyai S; Shanehbandi D; Mokhtarzadeh A; Aghebati-Maleki L; Shahgoli VK; Brunetti O; Rahmani S; Shadbad MA; Baghbanzadeh A; Silvestris N; Baradaran B
Life Sci; 2021 Oct; 282():119826. PubMed ID: 34265363
[TBL] [Abstract][Full Text] [Related]
14. 2-Substituted thienotetrahydropyridine derivatives: Allosteric ectonucleotidase inhibitors.
Schäkel L; Mirza S; Pietsch M; Lee SY; Keuler T; Sylvester K; Pelletier J; Sévigny J; Pillaiyar T; Namasivayam V; Gütschow M; Müller CE
Arch Pharm (Weinheim); 2021 Dec; 354(12):e2100300. PubMed ID: 34697820
[TBL] [Abstract][Full Text] [Related]
15. CD73 as a potential opportunity for cancer immunotherapy.
Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
[TBL] [Abstract][Full Text] [Related]
16. Targeting cancer-derived adenosine: new therapeutic approaches.
Young A; Mittal D; Stagg J; Smyth MJ
Cancer Discov; 2014 Aug; 4(8):879-88. PubMed ID: 25035124
[TBL] [Abstract][Full Text] [Related]
17. CD39 and CD73 in the aortic valve-biochemical and immunohistochemical analysis in valve cell populations and its changes in valve mineralization.
Kaniewska-Bednarczuk E; Kutryb-Zajac B; Sarathchandra P; Pelikant-Malecka I; Sielicka A; Piotrowska I; Slominska EM; Chester AH; Yacoub MH; Smolenski RT
Cardiovasc Pathol; 2018; 36():53-63. PubMed ID: 30056298
[TBL] [Abstract][Full Text] [Related]
18. Ectonucleotidases of the rabbit ciliary body nonpigmented epithelium.
Farahbakhsh NA
Invest Ophthalmol Vis Sci; 2003 Sep; 44(9):3952-60. PubMed ID: 12939314
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the T Cell Response by CD39.
Takenaka MC; Robson S; Quintana FJ
Trends Immunol; 2016 Jul; 37(7):427-439. PubMed ID: 27236363
[TBL] [Abstract][Full Text] [Related]
20. The role of the CD39-CD73-adenosine pathway in liver disease.
Wang S; Gao S; Zhou D; Qian X; Luan J; Lv X
J Cell Physiol; 2021 Feb; 236(2):851-862. PubMed ID: 32648591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
